MedElevator
Войти в исследования BMC ophthalmology · 2025
Comparison of effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren's syndrome.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jee Donghyun, Han Su Yeon, Kim Hyun Seung, Kim Eun Chul
Аннотация
PURPOSE: To compare the effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren's syndrome.
METHODS: 120 eyes of 60 patients who have been diagnosed with Sjögren's syndrome were retrospectively enrolled. Thirty patients (group 1, 60 eyes) were treated with cyclosporine 0.1% and 30 patients (group 2, 60 eyes) with cyclosporine 0.05%. Ocular Surface Disease Index Questionnaire (OSDI), Schirmer I test, noninvasive tear break up time (NItBUT), corneal staining score, MMP 9, meibography, meibum quality and expressibility scores, tear meniscus height, and impression cytology were examined before treatment and at 1 and 3 months after treatment.
RESULTS: All of dry eye signs and symptoms of both groups at 1 and 3 months were significantly improved compared with those before treatment, respectively (P < 0.05). OSDI, Schirmer I test, NItBUT, corneal and conunctival fluorescein score, MMP-9 grade, goblet cell density, and impression cytology grade of group1 were significantly improved compared with group 2 at 1 and 3 months after treatment (P < 0.05). The percentage of discontinued treatment in groups 1 and 2 was 26.7 and 3.3%, respectively.
CONCLUSION: Cyclosporine 0.1% was more effective for relieving inflammatory dry eye signs and symptoms but less tolerable compared with cyclosporine 0.05% in dry eye with Sjögren's syndrome.
METHODS: 120 eyes of 60 patients who have been diagnosed with Sjögren's syndrome were retrospectively enrolled. Thirty patients (group 1, 60 eyes) were treated with cyclosporine 0.1% and 30 patients (group 2, 60 eyes) with cyclosporine 0.05%. Ocular Surface Disease Index Questionnaire (OSDI), Schirmer I test, noninvasive tear break up time (NItBUT), corneal staining score, MMP 9, meibography, meibum quality and expressibility scores, tear meniscus height, and impression cytology were examined before treatment and at 1 and 3 months after treatment.
RESULTS: All of dry eye signs and symptoms of both groups at 1 and 3 months were significantly improved compared with those before treatment, respectively (P < 0.05). OSDI, Schirmer I test, NItBUT, corneal and conunctival fluorescein score, MMP-9 grade, goblet cell density, and impression cytology grade of group1 were significantly improved compared with group 2 at 1 and 3 months after treatment (P < 0.05). The percentage of discontinued treatment in groups 1 and 2 was 26.7 and 3.3%, respectively.
CONCLUSION: Cyclosporine 0.1% was more effective for relieving inflammatory dry eye signs and symptoms but less tolerable compared with cyclosporine 0.05% in dry eye with Sjögren's syndrome.